A medical worker in Beijing. Photo: Greg Baker/AFP via Getty Images

About 150 prescription drugs — including antibiotics, generics and some branded drugs without alternatives — are at risk of shortage if the coronavirus outbreak in China worsens, according to two sources familiar with a list of at-risk drugs compiled by the Food and Drug Administration.

Why it matters: China is a huge supplier of the ingredients used to make drugs that are sold in the U.S. If the virus decreases China's production capability, Americans who rely on the drugs made from these ingredients could be in trouble.

What they're saying: The FDA declined to comment on the list, but said in a statement that it's "keenly aware that the outbreak could impact the medical product supply chain," and has devoted additional resources toward identifying potential vulnerabilities to U.S. medical products stemming specifically from the outbreak.

  • The agency has been in contact with hundreds of drug and medical device manufacturers, and it's also coordinating with global regulators like the European Medicines Agency.
  • It pointed out that there aren't any vaccines, gene therapies or blood derivatives licensed by the FDA that are manufactured in China, although raw materials for many products do come from China and other southeastern Asian countries. The agency is in contact with biologics manufacturers to monitor supply concerns.
  • "If a potential shortage or disruption of medical products is identified by the FDA, we will use all available tools to react swiftly and mitigate the impact to U.S. patients and health care professionals," said an FDA spokesperson.

The intrigue: FDA commissioner Stephen Hahn is not a member of the task force that the administration has assembled to handle the coronavirus. Only two of the dozen members of the task force are physician-scientists, BioCentury noted on Friday.

  • Politico reported Friday night that the White House is worried about how the coronavirus outbreak could shape President Trump's re-election prospects, and some administration officials are concerned that the virus is already spreading within the U.S., undetected.

The bottom line: Whether or not the coronavirus spreads within the U.S., any potential drug shortages would be felt acutely by the American patients that rely on them.

Go deeper: Coronavirus outbreak fuels concerns about pharma's global supply chain

Go deeper

How small businesses got stiffed by the coronavirus pandemic

Illustration: Aïda Amer/Axios

The story of American businesses in the coronavirus pandemic is a tale of two markets — one made up of tech firms and online retailers as winners awash in capital, and another of brick-and-mortar mom-and-pop shops that is collapsing.

Why it matters: The coronavirus pandemic has created an environment where losing industries like traditional retail and hospitality as well as a sizable portion of firms owned by women, immigrants and people of color are wiped out and may be gone for good.

Apple's antitrust fight turns Epic

Illustration: Aïda Amer/Axios

Millions of angry gamers may soon join the chorus of voices calling for an antitrust crackdown on Apple, as the iPhone giant faces a new lawsuit and PR blitz from Epic Games, maker of mega-hit Fortnite.

Why it matters: Apple is one of several Big Tech firms accused of violating the spirit, if not the letter, of antitrust law. A high-profile lawsuit could become a roadmap for either building a case against tech titans under existing antitrust laws or writing new ones better suited to the digital economy.

Survey: Fears grow about Social Security’s future

Data: AARP survey of 1,441 U.S. adults conducted July 14–27, 2020 a ±3.4% margin of error at the 95% confidence level; Chart: Naema Ahmed/Axios

Younger Americans are increasingly concerned that Social Security won't be enough to wholly fall back on once they retire, according to a survey conducted by AARP — in honor of today's 85th anniversary of the program — given first to Axios.

Why it matters: Young people's concerns about financial insecurity once they're on a restricted income are rising — and that generation is worried the program, which currently pays out to 65 million beneficiaries, won't be enough to sustain them.